title: [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
abstract: OBJECTIVE
  To assess therapeutic and prophylactic effect of large-dose cerebrolysin (15 ml/day for 28 days) in hypertensive and atherosclerotic patients with cognitive disorders.
  
  
  METHODS
  Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study. The effect was stated by clinical status, neuropsychological and neurophysiological data.
  
  
  RESULTS
  In mild disturbances of cognitive functions in patients with arterial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and thinking which persist for at least a year after the course. The clinical data agree with positive trend in neurophysiological parameters of cognitive component of the response of evoked potentials P-300.
  
  
  CONCLUSIONS
  A course of 28-day annual treatment with cerebrolysin (15 ml/day) of patients with mild defects of cognitive functions stabilizes the process, leads to regression of cognitive disorders predicting vascular dementia.
authors.forename: N V
authors.initials: NV
authors.lastname: Vereshchagin
authors.forename: Z A
authors.initials: ZA
authors.lastname: Suslina
authors.forename: S L
authors.initials: SL
authors.lastname: Timerbaeva
authors.forename: E M
authors.initials: EM
authors.lastname: Kashina
authors.forename: V V
authors.initials: VV
authors.lastname: Gnezditskiĭ
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Maksimova
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Rebrova
authors.forename: I N
authors.initials: IN
authors.lastname: Smirnova
mesh_terms: D000368:Aged; D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications*; D003072:Cognition Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D013997:Time Factors
chemical_list: D000596:Amino Acids; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D010919:Placebos; C006952:cerebrolysin